Professor Andrew Baildam
Professor Andrew Baildam trained in surgical oncology and then additionally breast plastic and reconstructive surgery before appointment as Consultant Surgeon and Honorary Senior Lecturer in Surgical Oncology at The Christie Hospital in Manchester UK. Subsequently he was appointed to St Bartholomew’s Hospital in London as the Professor of Breast and Oncoplastic Surgery to the Queen Mary University of London. During his training he took two years in London and Manchester to research the molecular biology of breast cancer, leading to a Doctoral Thesis. With a keen interest in the care of patients with genetic breast cancer and oncoplastic breast surgery, he is hugely experienced in risk reducing surgery and breast reconstruction. He has over 180 peer reviewed publications, abstracts and chapters, and has innovated a number of approaches to breast cancer surgery. He has also held several positions including being the past
President of BASO-The Association of Cancer Surgery and the Chair of Royal College of Surgeons of England Cancer Surgery Committee. He is a member of BAPRAS, the Association of Plastic and Reconstructive Surgeons. Of note, he set up the cross specialty breast surgery oncoplastic fellowships in the UK, leading to a better-structured oncoplastic programme for surgical trainees. He is enthusiastic and passionate both for the highest quality care for patients, and for inspiration of trainees, and has a high tertiary referral surgical practice in Manchester at the Alexandra Hospital and London at King Edward VII Hospital. He teaches and lectures widely and spends off-work time climbing mountains and enjoying music and art.
Professor Shelley Hwang
Dr Shelley Hwang is Professor of Surgical Oncology and Radiology, Chief of Breast Surgery and Vice Chair of Research for the Duke Department of Surgery and the Duke University Comprehensive Cancer Center, where she co-leads the Women’s Cancer Program. Her national leadership roles include membership on the NCI Breast Cancer Steering Committee and the NCCN Screening Guidelines Committee and she has also participated on national guidelines panels for DCIS and node-positive breast cancer. Her research focus includes breast cancer prevention, identifying less invasive treatments for early stage breast cancers including DCIS, and understanding the genetic and stromal determinants of cancer progression. Her collaborations also include studies related to immune approaches to breast cancer treatment and her team has been funded to study PVSRIPO vaccine therapy for advanced breast cancer. Dr Hwang is an experienced clinical trialist with a 20-year interest in both the biology and treatment of early stage breast cancer and she is the national PI of a cooperative group study through the ALLIANCE, the COMET study, which evaluates the role of active surveillance compared to usual care for DCIS. She is coPI on the CRUK PRECISION Grand Challenge project, an international, multicentre collaboration around reducing overtreatment in early stage breast cancer. Her group has been selected for the Precancer Atlas U01 award, one of the Moonshot initiatives.